Educational research & price index · Independent Janoshik & MZ Biolabs COA verification

← Verified COAs & $/mg for this compound

Guide|36 CitationsGLP-1 & MetabolicFemale-friendly

Tirzepatide Research Dosing Reference

Also known as: Mounjaro, Zepbound, Dual GIP/GLP-1 Agonist, Tirz

Dose Range
2.5–10 mgResearch range
0Typical research window: 2.5–10 mg15 mg

Studied in SURMOUNT Phase 3 human RCTs (Jastreboff et al., NEJM). Initiation dose is 2.5 mg once weekly for 4 weeks.

Protocol at a Glance
How Often
Once weekly

Once every 7 days SubQ (starting at 2.5 mg/wk for 4 weeks)

A Typical Run
12–52 weeks

Stepwise 4-week titration (2.5 mg → 5 mg → 7.5 mg → 10–15 mg once weekly).

How It's Taken
Vial

SubQ injection once weekly

Evidence
Established

FDA-approved (Mounjaro / Zepbound) & SURMOUNT Phase 3 RCTs

Half-Life & 72-Hour Clearance Shape
~5 days

~5 days (~120 hours) half-life via albumin-binding C20 fatty diacid moiety

0h18h36h54h72h
On Your SyringeU-100 Insulin Syringe

A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.

10 mg vial · 2 mL water · 0.5 mL syringe
Concentration: 5 mg in every mL (50 mcg per unit)
0u10u20u30u40u50u
Low end: 2.5 mg50 units
High end: 10 mg200 units

All U-100: 100 units = 1 mL. 4 doses in the vial at the low end (1 doses at the high end).

Track the doses you run

Save Tirzepatide to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.

Verified Peptide Vial Suppliers · Sorted by Real $/mg•Checked Nov 11, 2026

Tirzepatide supplier & $/mg comparison.

Source:
Max $/mg:
Sort:
Elite Research USA
Batch COA on product page
US Domestic Vial
List price
$160.00
60mg vial, sold as “ER-TZ”
$2.67/mg
Ascension Peptides50% OFF AUTO-APPLIED
Batch COAs (Kovera Labs, MZ Biolabs) on product page
US Domestic Vial
50% Off First Order Link
$90.00 net$180.00
30mg vial, sold as “T-30”
$3.00/mg$6.00/mg retail
Peptyes
Horizon Analytical UPLC-MS COA, lot DPS-2934068 (99.39%); COA names Privilege Bio Labs (Peptyes says: its manufacturer)
US Domestic Vial
List price (verified Nov 11, 2026); code PEPTIDEPROTOCOLS takes 10% off at checkout
$96.00
30mg vial, sold as “GLP-1/GIP (T)” (vendor code name; compound per COA identity result)
$3.20/mg
Bulletproof BioLabs
ILS Laboratories HPLC COA COA-2026-RNV3HI, lot BPB-2610-001
US Domestic Vial
Vendor-supplied list price (Nov 7, 2026; store requires login)
$105.00
30mg vial, sold as “GLP-2 TZ” (vendor code name; compound mapping confirmed by vendor)
$3.50/mg
Polaris Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$309.00
60mg vial
$5.15/mg
Direct Peptides
COA per store product page
US Domestic Vial
List price (last verified Nov 4, 2026; store now requires sign-in)
$179.00
30mg DP2-T
$5.97/mg
Protide Health
Per-lot COA (Freedom Diagnostics, HPLC-MS) on product page
US Domestic Vial
List price
$400.00
60mg vial, sold as “GLP-2”
$6.67/mg
Pure Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026); code PEPTIDE9544 takes 10% off at checkout
$150.00
20mg vial, sold as “Pure-TRZ-2”
$7.50/mg
Sorted strictly by calculated $/mg or 2026 COA score. Only research peptide vial suppliers are included in $/mg benchmarks.
Full Verified $/mg Index →

At a Glance · 2026 FDA / 503A / WADA / Evidence Profile

FDA-Approved MedicationTier 1 — Human Phase 3 RCT / Approved
Pharmacological Class
Dual GIP & GLP-1 Incretin Receptor Co-Agonist
Administration Route
Under-the-skin injection (Subcutaneous)
2026 FDA & 503A Status
FDA-approved prescription drug (NDA). Following 2025/2026 FDA shortage resolution rulings, routine 503A/503B commercial copycat compounding is restricted; available via branded Rx or qualified physician telehealth protocols.
WADA Sport Status
Prohibited at All Times (WADA S0 Unapproved Substances & S2.2 Peptide Hormones, Growth Factors & Mimetics)
Evidence Tier
Tier 1 — Human Phase 3 RCT / Approved: Multi-center randomized controlled human clinical trials (Phase 3) and/or regulatory approval
What is a GLP-1 Agonist?

A molecule that mimics glucagon-like peptide-1 (GLP-1), a hormone that regulates blood sugar, slows gastric emptying, and reduces appetite. Semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound) are GLP-1 agonists. These are peptides, but they are marketed and prescribed as pharmaceutical drugs.

Tirzepatide is the same active compound as Mounjaro, Zepbound (Eli Lilly). FDA approved for: Type 2 diabetes, Chronic weight management.

Bottom Line Up Front

Tirzepatide is a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and obesity. It produces greater weight loss than semaglutide in head-to-head trials. The most effective obesity medication currently available.

Best evidence for

Type 2 diabetes, chronic weight management

Weakest evidence for

Non-diabetic metabolic health

Pharma equivalent

Mounjaro, Zepbound (Eli Lilly)

Studies on file

36 (33 human)

EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. Tirzepatide is not FDA approved for human use (unless specified above). This information does not constitute medical advice.

Overview

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It represents a new class of medications for diabetes and obesity, showing superior weight loss compared to GLP-1 agonists alone.

Mechanisms of Action

  • Dual agonist at GIP and GLP-1 receptors
  • Enhanced insulin secretion vs GLP-1 alone
  • Superior appetite suppression
  • Improved lipid metabolism
  • Enhanced energy expenditure

Research Protocols

Summaries of published research. For educational purposes only.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLinkSave
SURMOUNT-1 Obesity Trial
published study
15 mgWeekly72 weeksSubcutaneoushuman
Tirzepatide to Retatrutide Switch Protocol
reported protocol
Variable (per current Tirzepatide dose)WeeklySwitch at 2 months, continue RetatrutideSubcutaneoushuman—
Baseline & Mid-Cycle Biomarker Bloodwork Panel

Metabolic, Hepatic & Incretin Safety Biomarker Panel (Tirzepatide)

Quantify visceral fat mobilization, insulin resistance reversal, hepatic steatosis (MASH) clearance, and pancreatic/renal safety during metabolic protocols.

Draw fasted morning labs at Baseline (Day 0) and Mid-Cycle (Week 6–8)

HbA1c & Fasting Insulin (HOMA-IR)

Day 0 + Wk 6–8

Why track at baseline: Measures baseline hyperinsulinemia and 90-day glycemic load prior to incretin or lipolytic initiation.

Week 6–8 check: Track rapid drop in Fasting Insulin (often 30%–50% reduction by Week 6–8) and normalizing HbA1c.

ALT, AST & GGT Liver Enzymes

Day 0 + Wk 6–8

Why track at baseline: Dual/triple agonists (Retatrutide, Mazdutide, Pemvidutide) mobilize 65%–80% of intrahepatic triglycerides.

Week 6–8 check: Confirm progressive reduction in ALT/AST (<25 U/L) as hepatic steatosis clears.

ApoB, Triglycerides & Advanced Lipid Panel

Day 0 + Wk 6–8

Why track at baseline: Quantifies atherogenic particle burden and VLDL triglyceride export before weight loss.

Week 6–8 check: Expect 20%–40% triglyceride drop and significant ApoB improvement alongside visceral fat loss.

Serum Lipase, Amylase & eGFR / Cystatin C

Day 0 + Wk 6–8

Why track at baseline: Essential safety screen for subclinical pancreatic inflammation and hydration/renal filtration.

Week 6–8 check: Ensure Lipase stays within reference range and eGFR remains stable with adequate electrolyte hydration.

Test before and during your protocol: one baseline panel of 100+ Quest biomarkers covering the markers above, plus a mid-cycle retest. No doctor visit required.Code SPAMBASSADOR
Get baseline bloodwork at Superpower

Related Studies

33 Human3 Animal

Among 41&#x202f;222 adults meeting the study criteria (semaglutide, 32&#x202f;029; tirzepatide, 9193), 18&#x202f;386 remained after propensity score matching. The mean (SD) age was 52.0 (12.9) years, 12&#x202f;970 were female (70.5%), 14&#x202f;182 were white (77.1%), 2171 Black (11.8%), 354 Asian (1.9%), 1679 were of other or unknown race, and 9563 (52.0%) had T2D.

Limitations: No placebo control reported.

2025|JAMA internal medicine
PubMed

The 160 participants (pooled tirzepatide doses n&#x2009;=&#x2009;124, placebo n&#x2009;=&#x2009;36) with baseline and end of study DXA data were 73% female and had a mean weight of 102.5&#x2009;kg and body mass index of 38.0&#x2009;kg/m2. The change in body weight, fat mass and lean mass from baseline to Week 72 was -21.3%, -33.9% and -10.9% with tirzepatide and -5.3%, -8.2% and -2.6% with placebo, respectively (p&#x2009;<&#x2009;0.001 for all comparisons).

Limitations: Standard limitations apply. Check original paper for full discussion.

2025|Diabetes, obesity &amp; metabolism
PubMed

A total of 751 participants underwent randomization. The least-squares mean percent change in weight at week 72 was -20.2% (95% confidence interval [CI], -21.4 to -19.1) with tirzepatide and -13.7% (95% CI, -14.9 to -12.6) with semaglutide (P<0.001).

Limitations: No placebo control reported.

2025|The New England journal of medicine
PubMed

In the clinical trial, tirzepatide appeared to have no impact on metabolic adaptation but led to increased fat oxidation and reductions in appetite and calorie intake during an ad libitum test meal (vs. This is the first study to provide insights into the mechanisms of action of tirzepatide on weight loss with respect to calorie intake, energy expenditure, and macronutrient utilization.

Limitations: Standard limitations apply. Check original paper for full discussion.

2025|Cell metabolism
PubMed

Between May 10, 2021, and June 24, 2023, 413 participants were screened, and 267 were randomly assigned. Due to exclusion of one study site, the mITT population was 225 participants (133 [59%] men and 92 [41%] women, mean age 50&#xb7;8 [SD 10&#xb7;7] years), with 73 in the tirzepatide 10 mg group, 77 in the tirzepatide 15 mg group, and 75 in the placebo group, of whom 192 (85%) completed both study and treatment.

Limitations: Standard limitations apply. Check original paper for full discussion.

2025|The lancet. Diabetes &amp; endocrinology
PubMed

Benchmarking of the 2 trial emulations demonstrated high agreement on all prespecified metrics. In analyses using expanded eligibility criteria, 58&#x202f;333 patients were included in the semaglutide vs sitagliptin cohort, 11&#x202f;257 for tirzepatide vs sitagliptin, and 28&#x202f;100 for tirzepatide vs semaglutide.

Limitations: Standard limitations apply. Check original paper for full discussion.

2025|JAMA
PubMed

Whether cardiovascular benefits will be found with dual GLP-1/GIP receptor agonists remains uncertain, and the contribution of GIP receptor activation to cardiovascular risk has not been established. Several ongoing large-scale cardiovascular outcome trials for tirzepatide will provide a clearer understanding of where tirzepatide should be positioned in the treatment of established atherosclerotic cardiovascular disease or in people at high risk, in relation to current standard-of-care cardioprotective agents and approaches.

Limitations: Review article — no new primary data.

2025|The Journal of endocrinology
PubMed

A total of 282 adults were randomly assigned to tirzepatide (n&#x2009;= 139) or dulaglutide (n&#x2009;= 143). Change from baseline in HbA1c at week 40 was -1.44% (SE, 0.07) with tirzepatide, 15 mg or MTD, and -0.67% (SE, 0.08) with dulaglutide, 4.5 mg or MTD (estimated treatment difference, -0.77% [95% CI, -0.98% to -0.56%; P&#x2009;<&#x2009;0.001]).

Limitations: No placebo control reported.

2025|Annals of internal medicine
PubMed

Tirzepatide also results in clinically important improvements in multiple obesity-related complications including sleep apnea, metabolic-dysfunction associated steatohepatitis, heart failure with preserved ejection fraction and diabetes prevention. Ongoing trials will provide further data on tirzepatide's long-term safety, efficacy (including cardiovascular outcomes) and potential cost-effectiveness for managing overweight/obesity and/or T2D.

Limitations: No placebo control reported. Review article — no new primary data.

2024|Expert opinion on pharmacotherapy
PubMed

The most common adverse events were usually short-lived gastrointestinal-related events, which were generally mild to moderate in nature, including nausea, diarrhoea, decreased appetite and vomiting. Tirzepatide is a valuable addition to the treatment options for people with inadequately controlled T2DM.

Limitations: No placebo control reported. Review article — no new primary data.

2024|Drugs
PubMed

Of the 6 articles included in the review, one investigated the use of tirzepatide and showed a statistically significant reduction in area under the plasma drug concentration-time curve, maximum concentration, and time to maximum plasma concentration when tirzepatide was concomitantly administered with an oral hormonal contraceptive. The remaining 5 studies involving GLP-1 RAs did not show a statistically or clinically significant difference of impact of the agents on oral hormonal contraceptives.

Limitations: No placebo control reported. Review article — no new primary data.

2024|Journal of the American Pharmacists Association : JAPhA
PubMed

Body weight, BMI, WC, FM, FBG, LDL-C, TC, TG and HOMA-IR were significantly decreased in Ex+P, Ex+T5 and Ex+T2.5 groups compared to Placebo, T5 and T2.5 groups. WHR significantly decreased in Ex+P, Ex+T5 and Ex+T2.5 groups compared to Placebo group.

Limitations: Standard limitations apply. Check original paper for full discussion.

2024|Clinical hemorheology and microcirculation
PubMed

A total of 12 randomized controlled trials were included, with a total of 11,758 patients. Meta analysis results showed that compared with the glucagon like peptide-1 receptor agonist (GLP-1 RAs), placebo and insulin groups, tirzepatide could significantly reduce the BMI (body mass index) of patients [MD&#x2009;=&#x2009;-1.71, 95% CI (-2.46, -0.95), p&#x2009;&#x2009;0.05).

Limitations: Review article — no new primary data.

2024|Frontiers in public health
PubMed

There were 14&#x202f;834 patients treated with tirzepatide (mean [SD] age, 55.4 [11.8] years; 8444 [56.9%] female) and 125&#x202f;474 treated with GLP-1 RA (mean [SD] age, 58.1 [13.3] years; 67&#x202f;474 [53.8%] female). After a median (IQR) follow-up of 10.5 (5.2-15.7) months, 95 patients (0.6%) in the tirzepatide group and 166 (1.1%) in the GLP-1 RA group died.

Limitations: No placebo control reported.

2024|JAMA network open
PubMed

Tirzepatide treatment demonstrated significant reductions in body weight compared with placebo and semaglutide, resulting in greater fat mass reduction. Tirzepatide and semaglutide significantly reduced appetite versus placebo.

Limitations: Standard limitations apply. Check original paper for full discussion.

2023|Diabetes care
PubMed

Evidence from five SURPASS clinical trials has demonstrated that tirzepatide has potent glucose lowering and weight loss with adverse effects comparable to GLP-1 receptor agonists. This paper gives an overview of tirzepatide and SURPASS clinical trials.

Limitations: No placebo control reported.

2023|The Senior care pharmacist
PubMed

Among 1428 randomized participants (824 [57.7%] women; mean [SD] age, 58.8 [9.7] years; mean [SD] HbA1c, 8.8% [1.0%]), 1304 (91.3%) completed the trial. At week 52, estimated mean change from baseline in HbA1c with tirzepatide (pooled cohort) was -2.1% vs -1.1% with insulin lispro, resulting in mean HbA1c levels of 6.7% vs 7.7% (estimated treatment difference, -0.98% [95% CI, -1.17% to -0.79%]; P&#x2009;<&#x2009;.001); results met noninferiority criteria and statistical superiority was achieved.

Limitations: No placebo control reported.

2023|JAMA
PubMed

In people without diabetes, tirzepatide 5 to 15 mg once weekly for the treatment for obesity (SURMOUNT-1) resulted in substantial reductions in body weight (16.5% to 22.4%) over 72 weeks. Overall, the SURPASS program and SURMOUNT-1 study suggest that tirzepatide is marking a new era in T2DM and/or obesity management through dual agonism of gut hormones.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

2023|Journal of obesity &amp; metabolic syndrome
PubMed

Moreover, tirzepatide also decreased eGFR slopes in participants with eGFR >60&#xa0;mL/min/1.73 m2 or with normoalbuminuria. We now review the potential kidney health implications of tirzepatide, addressing its structure and function, relationship to current GLP1 receptor agonists, impact of recent results for the treatment and prevention of kidney disease, and expectations for the future.

Limitations: No placebo control reported. Review article — no new primary data.

2023|Clinical kidney journal
PubMed

Ten trials (6836 participants) were included. Gastrointestinal (GI) AEs were the most commonly reported AEs and were dose dependent 39% (95% CI, 35%-43%), 46% (95% CI, 42%-49%), and 49% (95% CI, 38%-60%) for the 5, 10, and 15&#x2005;mg dose, respectively.

Limitations: No placebo control reported. Review article — no new primary data.

2023|Journal of the Endocrine Society
PubMed

RCTs included in this study revealed that among 5800 patients, 78.22% (95%.

Limitations: Review article — no new primary data.

2023|International journal of obesity (2005)
PubMed

A total of nine trials with 9871 participants (6828 in the tirzepatide group and 3043 in the control group) that met the pre-specified criteria were included. When compared to all control groups consisting of basal insulin (glargine or degludec), selective GLP1-RA (dulaglutide or semaglutide once weekly), and placebo, an increased risk of pancreatitis was not found to be significantly associated with tirzepatide (RR 1.46, [95% CI] 0.59 to 3.61; I2&#xa0;=&#xa0;0.0%, p = 0.436).

Limitations: Review article — no new primary data.

2023|Frontiers in endocrinology
PubMed

The tirzepatide cardiovascular outcomes trial (SURPASS-CVOT) is in progress and is expected to be completed in the fall of 2024. Tirzepatide represents an attractive new option and first-in-class agent for the treatment of T2D in people unable to achieve their glycaemic or weight management goals.

Limitations: Review article — no new primary data.

2023|Drugs in context
PubMed

Among 475 randomized participants (211 [44%] women; mean [SD] age, 60.6 [9.9] years; mean [SD] HbA1c, 8.31% [0.85%]), 451 (94.9%) completed the trial. Treatment was prematurely discontinued by 10% of participants in the 5-mg tirzepatide group, 12% in the 10-mg tirzepatide group, 18% in the 15-mg tirzepatide group, and 3% in the placebo group.

Limitations: Standard limitations apply. Check original paper for full discussion.

2022|JAMA
PubMed

Moreover, it remains to be shown that GIPR agonism can improve insulin secretion in type 2 diabetic patients who have been noted in previous studies to be unresponsive to GIP. Certainly, the apparent advantage of tirzepatide, a dual incretin agonist, over GLP-1RA will spark renewed interest in the therapeutic potential of GIP in type 2 diabetes, obesity and related co-morbidities.

Limitations: No placebo control reported. Review article — no new primary data.

2022|Cardiovascular diabetology
PubMed

Seven trials (6609 participants) were included. A dose-dependent superiority in lowering HbA1c was evident with all three tirzepatide doses vs all comparators, with mean differences ranging from -17.71&#xa0;mmol/mol (-1.62%) to -22.35&#xa0;mmol/mol (-2.06%) vs placebo, -3.22&#xa0;mmol/mol (-0.29%) to -10.06&#xa0;mmol/mol (-0.92%) vs GLP-1 RAs, and -7.66&#xa0;mmol/mol (-0.70%) to -12.02&#xa0;mmol/mol (-1.09%) vs basal insulin regimens.

Limitations: Review article — no new primary data.

2022|Diabetologia
PubMed

From April 1, 2019, to Nov 15, 2019, 502 participants were assessed for eligibility to participate in this substudy, 296 (59%) of whom were included in the enrolled MRI population and randomly assigned to treatment (tirzepatide 5 mg, n=71; tirzepatide 10 mg, n=79; tirzepatide 15 mg, n=72; and insulin degludec, n=74). Baseline demographics and clinical characteristics were similar across all treatment groups.

Limitations: No placebo control reported.

2022|The lancet. Diabetes &amp; endocrinology
PubMed

Tirzepatide is in phase III development for heart failure, obesity and cardiovascular disorders in T2DM, and in phase II development for non-alcoholic steatohepatitis. This article summarizes the milestones in the development of tirzepatide leading to this first approval for T2DM.

Limitations: No placebo control reported. Review article — no new primary data.

2022|Drugs
PubMed

Between May 7, 2019, and March 31, 2021, 821 participants were assessed for study eligibility and 636 were randomly assigned to receive at least one dose of tirzepatide 5 mg (n=159), 10 mg (n=158), or 15 mg (n=160), or dulaglutide 0&#xb7;75 mg (n=159). 615 (97%) participants completed the study and 21 (3%) discontinued.

Limitations: No placebo control reported.

2022|The lancet. Diabetes &amp; endocrinology
PubMed

Between June 28, 2019, and April 8, 2021, we screened 184 individuals and enrolled 117 participants, all of whom were included in the safety population (45 in the tirzepatide 15 mg group, 44 in the semaglutide 1 mg group, and 28 in the placebo group). Because of discontinuations and exclusions due to missing or unevaluable data, 39 patients in each treatment group and 24 patients in the placebo group comprised the pharmacodynamic analysis set.

Limitations: Standard limitations apply. Check original paper for full discussion.

2022|The lancet. Diabetes &amp; endocrinology
PubMed

Tirzepatide Once Weekly for the Treatment of Obesity. (The New England journal of medicine, 2022)

Limitations: No placebo control reported.

2022|The New England journal of medicine
PubMed

From June 3, 2019, to Oct 28, 2020, of 705 individuals assessed for eligibility, 478 (mean baseline HbA1c 7&#xb7;9% [63 mmol/mol], age 54&#xb7;1 years [SD 11&#xb7;9], 231 [48%] women, diabetes duration 4&#xb7;7 years, and body-mass index 31&#xb7;9 kg/m2) were randomly assigned to tirzepatide 5 mg (n=121 [25%]), tirzepatide 10 mg (n=121 [25%]), tirzepatide 15 mg (n=121 [25%]), or placebo (n=115 [24%]). 66 (14%) participants discontinued the study drug and 50 (10%) discontinued the study prematurely.

Limitations: Standard limitations apply. Check original paper for full discussion.

2021|Lancet (London, England)
PubMed

Experiments in primary islets reveal &#x3b2;-arrestin1 limits the insulin response to GLP-1, but not GIP or tirzepatide, suggesting that the biased agonism of tirzepatide enhances insulin secretion. Imbalance toward GIP receptor, combined with distinct signaling properties at the GLP-1 receptor, together may account for the promising efficacy of this investigational agent.

Limitations: Animal study only — human translation uncertain.

2021|JCI insight
PubMed

This information is based on available published literature. It should not take the place of medical care and advice from your healthcare provider.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

2021|The Journal of clinical investigation
PubMed

Homeostatic model assessment (HOMA) 2-B significantly increased with dulaglutide and tirzepatide 5, 10, and 15 mg compared with placebo (P &#x2264; .02). Proinsulin/insulin and proinsulin/C-peptide ratios significantly decreased with tirzepatide 10 and 15 mg compared with placebo and dulaglutide (P &#x2264; .007).

Limitations: Standard limitations apply. Check original paper for full discussion.

2021|The Journal of clinical endocrinology and metabolism
PubMed

Between April 1 and Nov 15, 2019, we assessed 1947 participants for eligibility, 1444 of whom were randomly assigned to treatment. The modified intention-to-treat population was 1437 participants from the tirzepatide 5 mg (n=358), tirzepatide 10 mg (n=360), tirzepatide 15 mg (n=359), and insulin degludec (n=360) groups.

Limitations: No placebo control reported.

2021|Lancet (London, England)
PubMed

Community Outcomes

Community Data Coming Soon

Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!

Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.

Important Warnings

  • •Boxed warning for thyroid C-cell tumors in rodents
  • •Pancreatitis risk
  • •Severe gastrointestinal adverse reactions
  • •Acute gallbladder disease
Sourcing, Diagnostic Bloodwork & Telehealth Pathways

Where to get Tirzepatide, baseline labs & clinician oversight.

Full Tirzepatide $/mg comparison →
50% OFF AUTO-APPLIED$3.00/mg net

Ascension Peptides (US Vials)

MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.

MZ Biolabs COA (Grade A)Claim 50% Off
Verified Vial SuppliersGrade A COA

SwissChems & Limitless Biotech

Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).

LABS & 503A CLINICS$199/yr Labs · Rx Consult

Superpower Labs & 503A Telehealth

Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.

Code:SPAMBASSADOR

Where to buy Tirzepatide: best verified price

Prices checked Nov 11, 2026 · sorted by $/mg · RUO

  1. 1. Elite Research USA — $2.67/mg (60mg vial, sold as “ER-TZ”, $160.00)
  2. 2. Ascension Peptides — $3.00/mg (30mg vial, sold as “T-30”, $90.00)
  3. 3. Peptyes — $3.20/mg (30mg vial, sold as “GLP-1/GIP (T)” (vendor code name; compound per COA identity result), $96.00)

Where is the cheapest place to buy Tirzepatide?

As of Nov 11, 2026, the lowest verified US domestic single-vial price we found is Elite Research USA at $2.67/mg (60mg vial, sold as “ER-TZ”, $160.00). We compared 8 US suppliers with live, checked prices.

How much does Tirzepatide cost per mg?

Verified US domestic prices currently range from $2.67/mg to $7.50/mg depending on supplier and vial size. Larger vials usually lower the $/mg.

How are these prices verified?

Each price is read from the supplier's own product page or store data and divided by the vial's mg. Suppliers we could not verify are left out rather than estimated. Tables sort strictly by $/mg, never by partner status. Prices are re-checked weekly on our price index.

Is Tirzepatide approved for human use?

Products from these suppliers are sold for laboratory research use only (RUO). This page is an educational price reference, not medical advice.

All compounds $/mgWeekly $/mg price indexReconstitution calculatorFree cheat sheet

FREE 1-PAGE PDF CHEAT SHEET

Peptide Reconstitution & U-100 Syringe Cheat Sheet

Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.

Unsubscribe anytime.Direct PDF Download

Related Peptides

Vendor vs vendor: price per mg

Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.

Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →

Common questions

How many peptides are in the database?

100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.

Where can I compare peptide prices?

Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.